Peritumoral administration of IFNβ upregulated mesenchymal stem cells inhibits tumor growth in an orthotopic, immunocompetent rat glioma model

BACKGROUND: Immunotherapy with IFNβ is a promising strategy for treating malignant glioma. However, systemic administration of IFNβ is inadequate because of low intratumoral concentration and major adverse effects. This study aimed to determine whether mesenchymal stem cells (MSCs) can be used as ce...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Immunother Cancer
Egile Nagusiak: Mao, Jiaji, Cao, Minghui, Zhang, Fang, Zhang, Jingzhong, Duan, Xiaohui, Lu, Liejing, Yang, Zehong, Zhang, Xiang, Zhu, Wangshu, Zhang, Qinyuan, Wang, Zhe, Shen, Jun
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2020
Gaiak:
Clinical/Translational Cancer Immunotherapy
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7069318/
https://ncbi.nlm.nih.gov/pubmed/32169868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000164
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak